CLINICAL_TRIALS ClinicalTrials.gov record update

Real-world Clinical Outcomes, Patient Characteristics, and Treatment Patterns Among Patients With Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-negative, Claudin-18 Isoform 2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Treated With Zolbetuximab or Other First Line Treatments: A Cohort Study Using Secondary Data in Europe and Canada

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07858500
Title field or adapter rule: {'original_value': 'Real-world Clinical Outcomes, Patient Characteristics, and Treatment Patterns Among Patients With Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-negative, Claudin-18 Isoform 2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Treated With Zolbetuximab or Other First Line Treatments: A Cohort Study Using Secondary Data in Europe and Canada', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:31.078876+00:00
Published At: 2026-10-28T00:00:00+00:00
Record Updated At: 2026-10-28
Source Retrieved At: 2026-10-31T22:18:28.651351+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer", "Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer", "Metastatic Gastric Adenocarcinoma or Cancer", "Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-28", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07858500"
protocolSection.identificationModule.officialTitle: "Real-world Clinical Outcomes, Patient Characteristics, and Treatment Patterns Among Patients With Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-negative, Claudin-18 Isoform 2-positive Gastric or Gastroesophageal Junction Adenocarcinoma Treated With Zolbetuximab or Other First Line Treatments: A Cohort Study Using Secondary Data in Europe and Canada"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: null
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['Cohort A: zolbetuximab with platinum-fluoropyrimidine chemotherapy', 'Cohort C: off-label treatment with zolbetuximab'], 'description': 'Real-world exposure to zolbetuximab.', 'name': 'Zolbetuximab Exposure', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A: zolbetuximab with platinum-fluoropyrimidine chemotherapy'], 'description': 'Real-world exposure to platinum-based chemotherapy.', 'name': 'Platinum-based Chemotherapy Exposure', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort B: 1L treatment which did not contain zolbetuximab'], 'description': 'Real-world exposure to 1L treatment not containing zolbetuximab.', 'name': '1L Treatment Not Containing Zolbetuximab Exposure', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Cohort A: zolbetuximab with platinum-fluoropyrimidine chemotherapy'], 'description': 'Real-world exposure to fluoropyrimidine-based chemotherapy.', 'name': 'Fluoropyrimidine-based Chemotherapy Exposure', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.